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To elucidate the mechanisms responsible for cytoprotective effects of TNF receptor–
activated factor 2 (TRAF2) in the heart, we employed genetic gain- and loss-of-function
studies ex vivo and in vivo in mice with cardiac-restricted overexpression of TRAF2 (Myh6-
TRAF2LC). Crossing Myh6-TRAF2LC mice with mice lacking canonical signaling (Myh6-
TRAF2LC/Myh6-IkBaΔN) abrogated the cytoprotective effects of TRAF2 ex vivo. In contrast,
inhibiting the JAK/STAT pathway did not abrogate the cytoprotective effects of TRAF2.
Transcriptional profiling of WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-IkBaΔN mouse
hearts suggested that the noncanonical NF-kB signaling pathway was upregulated in the
Myh6-TRAF2LC mouse hearts. Western blotting and ELISA for the NF-kB family proteins
p50, p65, p52, and RelB on nuclear and cytoplasmic extracts from naive 12-week-old WT,
Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-IkBaΔN mouse hearts showed increased
expression levels and increased DNA binding of p52 and RelB, whereas there was no
increase in expression or DNA binding of the p50 and p65 subunits. Crossing Myh6-
TRAF2LC mice with RelB
–/+ mice (Myh6-TRAF2LC/RelB–/+) attenuated the cytoprotective
effects of TRAF2 ex vivo and in vivo. Viewed together, these results suggest that crosstalk
between the canonical and noncanonical NF-kB signaling pathways is required for
mediating the cytoprotective effects of TRAF2.
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Introduction
In response to myocardial injury, the adult heart is capable of  synthesizing an ensemble of  proteins that 
enable and facilitate cardiac repair and left ventricular (LV) remodeling. We and others have shown that 
cytokines released by cardiocytes and professional immune cells residing within the myocardium confer 
cytoprotective responses following myocardial injury (1). TNF, which is among the most studied cytokines 
released by the heart following tissue injury, provokes cell survival responses in isolated cardiac myocytes 
(2, 3) and confers protective responses following coronary artery ligation and/or ischemia reperfusion 
(I/R) injury (4–7). Thus far, 3 different mechanisms have been proposed to explain the cytoprotective 
effects of  TNF, including activation of  the neutral sphingomyelinase pathway through generation of  cera-
mide and/or sphingosine 1-phosphate (6), activation of  the JAK/STAT pathway by the survivor activating 
factor enhancement (SAFE) pathway (8), and most recently TNF-induced activation of  TNF receptor–acti-
vated factor 2 (TRAF2) (9–11).
TRAF2 is a canonical member of  the TRAF family (TRAF1–7) of  proteins that exhibit shared modu-
lar domains characteristic of  adapter proteins. TRAFs are critical for mediating signal transduction path-
ways initiated by members of  the TNF receptor family (TNFR), the TLR family, the IL-1 receptor family, 
and the RIG-I–like receptor family. All TRAF family members, with the exception of  TRAF1, contain 
a RING finger domain localized at their N-terminus. The RING finger domain is common to many E3 
ubiquitin ligases, which are crucial for the activation of  downstream signaling pathways. TRAF proteins 
mediate signaling through the canonical NF-κB1 and noncanonical NF-κB2 pathways, mitogen-activated 
protein kinases, and IFN-regulatory factors. Functionally, TRAFs control a plethora of  diverse cellular pro-
cesses, including cell survival, tissue homeostasis, cell proliferation, differentiation, cytokine production, 
autophagy, and mitophagy (11, 12). We have shown that the cytoprotective effects of  TRAF2 are mediated, 
To elucidate the mechanisms responsible for cytoprotective effects of TNF receptor–activated 
factor 2 (TRAF2) in the heart, we employed genetic gain- and loss-of-function studies ex vivo 
and in vivo in mice with cardiac-restricted overexpression of TRAF2 (Myh6-TRAF2LC). Crossing 
Myh6-TRAF2LC mice with mice lacking canonical signaling (Myh6-TRAF2LC/Myh6-IκBαΔN) 
abrogated the cytoprotective effects of TRAF2 ex vivo. In contrast, inhibiting the JAK/STAT 
pathway did not abrogate the cytoprotective effects of TRAF2. Transcriptional profiling of 
WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts suggested that the 
noncanonical NF-κB signaling pathway was upregulated in the Myh6-TRAF2LC mouse hearts. 
Western blotting and ELISA for the NF-κB family proteins p50, p65, p52, and RelB on nuclear 
and cytoplasmic extracts from naive 12-week-old WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-
IκBαΔN mouse hearts showed increased expression levels and increased DNA binding of p52 
and RelB, whereas there was no increase in expression or DNA binding of the p50 and p65 
subunits. Crossing Myh6-TRAF2LC mice with RelB
–/+ mice (Myh6-TRAF2LC/RelB
–/+) attenuated 
the cytoprotective effects of TRAF2 ex vivo and in vivo. Viewed together, these results suggest 
that crosstalk between the canonical and noncanonical NF-κB signaling pathways is required for 
mediating the cytoprotective effects of TRAF2.
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at least in part, through upregulation of  cytoprotective or structural genes downstream from NF-κB sig-
naling (13, 14). In subsequent studies, we showed that TNF/TRAF2-mediated signaling is cytoprotective 
through a potentially novel E3 ligase–dependent pathway that enables increased mitochondrial autophagy 
in cardiac myocytes (11). A recent study has also shown that genetic deletion of  TRAF2 triggers necroptot-
ic cell death through an NF-κB–independent pathway (10). In order to further explore the contribution of  
NF-κB–dependent cytoprotective effects of  TRAF2, we employed genetic gain- and loss-of-function studies 
ex vivo and in vivo. Here, we show the finding that RelB, a member of  the NF-κB2 family of  transcription 
factors involved in noncanonical NF-κB signaling, is upregulated by TRAF2 and is required for mediating 
the cytoprotective effects of  TRAF2 overexpression. We further show that the cytoprotective effects of  
TRAF2 are mediated by crosstalk between the canonical and noncanonical NF-κB signaling pathways, 
thereby revealing a complexity for NF-κB signaling in the heart.
Results
Role of  NF-κB signaling in the cytoprotective effects of  TRAF2. To determine whether the cardioprotective 
effects of  TRAF2 were mediated through an NF-κB–dependent pathway, we crossed mice overexpressing 
TRAF2 under the control of  the Myh6 promoter (Myh6-TRAF2LC) with mice overexpressing a mutated 
IκBα (IκBαΔN) under the control of  the Myh6 promoter (Myh6-IκBαΔN), to generate a line of  Myh6-TRA-
F2LC/Myh6-IκBαΔN double-transgenic mice. The baseline cardiac phenotype was not significantly different 
among 12-week-old WT, Myh6-IκBαΔN, and Myh6-TRAF2LC/Myh6-IκBαΔN mice (Supplemental Figure 
1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.98278DS1). 
Mouse hearts were subjected to 30 minutes of  no-flow ischemia, followed by 60 minutes of  reperfusion ex 
vivo. Figure 1A shows that Myh6-TRAF2LC mouse hearts had significantly improved recovery of  LV func-
tion (P < 0.001 overall) when compared with WT mouse hearts, as we have reported previously (9, 13). Strik-
ingly, the cytoprotective effects of  TRAF2 were completely abrogated in the Myh6-TRAF2LC/Myh6-IκBαΔN 
double-transgenic mice (P > 0.99 overall compared with WT). Of note, the degree of  recovery of  LV function 
Figure 1. Role of NF-κB signaling in TRAF2-mediated cytoprotection during I/R injury. (A) Percent recovery of left ventricular developed pressure 
(LVDP) following Langendorff perfusion of WT, Myh6-TRAF2LC, Myh6-IκBαΔN, and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts (n = 5–6/group) (*P < 0.05 
compared with WT by repeated measures analysis using mixed models methodology). (B) Creatine kinase (CK) release measured in the effluent follow-
ing 30 minutes of reperfusion (n = 7–9/group). (C) Representative images of Evans blue dye (EBD) uptake (scale bar: 50 μm) (data is representative of 4 
independent experiments). (D) Group data for EBD uptake as percent area (n = 4–5/group) (*P < 0.05 by 1-way ANOVA compared with WT controls). Data 
are presented as mean ± SEM.
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was not significantly (P > 0.99) different in the Myh6-IκBαΔN mice when compared with the WT 
mice. To determine whether the absence of  functional recovery in the Myh6-TRAF2LC/Myh6-IκBαΔN 
double-transgenic mouse hearts was the result of  increased myocyte injury, we measured creatine kinase 
(CK) release and Evans blue dye (EBD) uptake. As shown by the group data in Figure 1B, there was signifi-
cantly decreased CK release (P = 0.008) after I/R injury in the Myh6-TRAF2LC mouse hearts when com-
pared with WT; however, the CK release in the double-transgenic Myh6-TRAF2LC/Myh6-IκBαΔN mouse 
hearts was not significantly different (P > 0.99) from the values in WT mouse hearts. As shown by the repre-
sentative fluorescence photomicrographs (Figure 1C) and the group data (Figure 1D), there was a significant 
(P = 0.019) decrease in EBD uptake in the hearts of  the Myh6-TRAF2LC mice compared with WT hearts 30 
minutes after I/R injury, whereas the degree of  EBD uptake in the Myh6-TRAF2LC/Myh6-IκBαΔN mouse 
hearts was not significantly different (P > 0.99) from the values in WT mouse hearts. Viewed together, these 
results suggest that NF-κB is required for the cardioprotective effects of  TRAF2.
Role of  JAK/STAT signaling on the cytoprotective effects of  TRAF2. Previous studies have suggested that 
the cytoprotective effects of  TNF are mediated through the SAFE pathway, insofar as TNF-induced pre-
conditioning was sensitive to pharmacologic inhibition of  the JAK/STAT pathway (15, 16). To determine 
whether STAT3 was involved in the cytoprotective effects of  TRAF2, we performed I/R injury experi-
ments ex vivo in the presence or absence of  AG490, an inhibitor of  STAT3 phosphorylation. As shown in 
Supplemental Figure 2, there was increased phosphorylation of  STAT3 in the nucleus of  the diluent treated 
Myh6-TRAF2LC mouse hearts when compared with diluent-treated WT mouse hearts, which was attenuat-
ed by 10 μM AG490 (P = 0.033 compared with diluent treated Myh6-TRAF2LC mouse hearts), consistent 
with prior reports (15). However, recovery of  LV-developed pressure following I/R injury was not signifi-
cantly attenuated in the AG490-treated Myh6-TRAF2LC mouse hearts (P = 0.96 overall) when compared 
with diluent-treated Myh6-TRAF2LC mouse hearts (Figure 2A). Moreover, the TRAF2-mediated decrease 
in CK release and decrease in EBD uptake in the Myh6-TRAF2LC mouse hearts was not attenuated (P = 
0.27 for CK and P = 0.54 for EBD) by treatment with AG490 (Figures 2, B–D). Viewed together, these 
Figure 2. Role of JAK/STAT pathway in mediating the protective effects of TRAF2 during I/R injury. (A) Percent recovery of left ventricular developed 
pressure (LVDP) in the presence of 10 μM AG490 or diluent control in WT and Myh6-TRAF2LC mouse hearts (n = 5–7/group) (*P < 0.05 compared with WT by 
repeated measures analysis using mixed models methodology). (B) Creatine kinase (CK) release measured in the effluent following 30 minutes of reperfu-
sion (n = 5–6/group). (C) Representative images of Evans Blue dye (EBD) uptake (scale bar: 100 μm) (data is representative of 4 independent experiments). 
(D) Group data for EBD uptake (n = 4–5/group) (*P < 0.05 by 2-tailed t test compared with diluent controls). Data are presented as mean ± SEM.
4insight.jci.org   https://doi.org/10.1172/jci.insight.98278
R E S E A R C H  A R T I C L E
results suggest that, while STAT3 is activated in the hearts of  Myh6-TRAF2LC mice, STAT3 signaling is not 
required for the cytoprotective effects of  TRAF2 in the heart.
Transcriptional profiling of  Myh6-TRAF2LC and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. To explore 
the potential mechanisms responsible for the NF-κB–mediated cytoprotective effects of  TRAF2, we 
performed transcriptional profiling in 12-week-old naive WT, Myh6-TRAF2LC, Myh6-IκBαΔN, and 
Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. Figure 3A shows that there were 48 probe sets that were 
differentially regulated in the Myh6-TRAF2LC vs. WT mouse hearts and 284 probe sets that were differ-
entially regulated in the Myh6-TRAF2LC vs. Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. The salient 
finding shown by the Venn diagrams in Figure 3A is that, of  the 48 probe sets that were differential-
ly regulated in the Myh6-TRAF2LC vs. WT mouse hearts, 39 probe sets were normalized in the Myh6- 
TRAF2LC/Myh6-IκBαΔN mouse hearts (36 probes up and down and 3 probes down and up), suggesting that 
NF-κB–mediated signaling was responsible for the majority of  the changes in gene expression observed in 
the Myh6-TRAF2LC mouse hearts. Agglomerative hierarchical clustering of  the expression of  these 48 probe 
sets showed that Myh6-TRAF2LC mouse hearts clustered separately, whereas Myh6-IκBαΔN and Myh6-TRA-
F2LC/Myh6-IκBαΔN mouse hearts clustered with WT mouse hearts (Figure 3B), further suggesting that the 
differences in gene expression in the Myh6-TRAF2LC mouse hearts was mediated through NF-κB signaling. 
While the number of  mRNAs that were normalized in the Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts 
was too small to permit typical Gene Ontology or pathway interrogation, inspection of  the gene lists (Sup-
plemental Table 1) revealed that there were several genes involved in suppressing the canonical NF-κB sig-
naling (Tnip1 [FDR < 0.05] and Nfkbie [FDR < 0.20]), as well as several genes that were involved in upreg-
ulating noncanonical NF-κB signaling (Relb [FDR < 0.05], Traf3 [FDR < 0.05]).
Activation of  NF-κB signaling. To further interrogate the potential mechanism(s) through which NF-κB 
mediates the cytoprotective effects of  TRAF2, we performed Western blotting for the NF-κB family mem-
ber proteins p50, p65, p52, and RelB on nuclear and cytoplasmic extracts from naive 12-week-old WT, 
Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. The important finding shown by Fig-
ure 4, A and B, is that the expression of  NF-κB family members that are traditionally associated with non-
canonical NF-κB signaling, namely p52 and RelB, was significantly increased in the nucleus (P = 0.008 for 
RelB, P = 0.035 for p52) and cytoplasm (P = 0.009 for RelB, P = 0.026 for p52) of  Myh6-TRAF2LC mouse 
hearts when compared with WT mouse hearts; however, there was no significant increase in p50 and p65 
subunits in the nucleus (P = 0.89 for p50, P = 0.45 for p65) or cytoplasm (P = 0.63 for p50, P = 0.06 for p65) 
of  Myh6-TRAF2LC mouse hearts when compared with WT mouse hearts, which are the subunits tradition-
ally associated with canonical NF-κB signaling. Importantly, the expression of  p52 and RelB subunits in 
Figure 3. Transcriptional profiling of WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-IκBαΔN mice. (A) Venn diagram of genes differentially regulated 
(absolute fold-change ≥ 1.2, FDR < 0.05) in Myh6-TRAF2LC vs. WT, and Myh6-TRAF2LC/Myh6-IκBαΔN vs. Myh6-TRAF2LC mice (n = 4/group); the overlap shows 
genes that are regulated in opposite directions. (B) Hierarchical clustering based on significantly different genes in Myh6-TRAF2LC vs. WT mouse hearts.
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the nuclear (P = 0.82 for p52, P = 0.48 for RelB) and cytosolic extracts (P = 0.38 for p52, P > 0.99 for RelB) 
from the Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts was not significantly different from values in WT 
mouse hearts. The functional activity of  p50, p65, p52, and RelB subunits was evaluated using a DNA-bind-
ing ELISA. Figure 4C shows that there was significantly increased binding of  p52 (P < 0.001) and RelB (P 
= 0.022) to NF-κB consensus oligonucleotides in the nuclear extracts from Myh6-TRAF2LC mouse hearts 
when compared with WT, which was significantly attenuated in the Myh6-TRAF2LC/Myh6-IκBαΔN mouse 
hearts (P > 0.99 compared with WT). There was, however, no increase in binding of  canonical NF-κB fam-
ily members, p50 (P = 0.41) and p65 (P = 0.34), in the Myh6-TRAF2LC mouse hearts, consistent with our 
prior study (17). Viewed together, these results suggest that TRAF2 overexpression leads to activation of  
noncanonical NF-κB signaling that is mediated via the canonical NF-κB signaling pathway.
Noncanonical NF-κB signaling in Myh6-TRAF2LC mouse hearts. NF-κB–inducing kinase (NIK; MAP3K) 
is a central signaling component of  the noncanonical NF-κB pathway. Under normal conditions NIK pro-
teins are kept at low levels through continuous degradation mediated by TRAF2 and TRAF3 (18). If  NIK 
is allowed to accumulate, it initiates IKKα-mediated phosphorylation of  p100, resulting in partial proteo-
somal degradation of  p100 and release of  p52 (the N-terminus of  p100), which preferentially complexes 
with RelB and translocates to the nucleus. As shown in Supplemental Figure 3A, NIK was not detectable in 
the cytosolic extracts from WT, Myh6-TRAF2LC, Myh6-IκBαΔN, or Myh6-TRAF2LC/Myh6-IκBαΔN mouse 
hearts, despite using an antibody that was able to detect a transfected NIK construct. Supplemental Figure 
3B shows that there was increased p100 translocation to the nucleus, a feature of  constitutive p100 pro-
cessing (19), as well as increased constitutive processing of  p100 to p52 in cytosolic and nuclear extracts of  
Myh6-TRAF2LC mouse hearts when compared with WT and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts 
(Supplemental Figure 3B). Viewed together, these observations are consistent with increased activation of  
the noncanonical NF-κB signaling pathway in the Myh6-TRAF2LC mouse hearts.
Figure 4. Activation of NF-κB signaling. (A) Western blot analysis of NF-κB family members (representative images of 3 independent experiments). (B) 
Quantification of grouped Western blot data (n = 3–4/group). (C) NF-κB family ELISA (n = 4–7/group). (*P < 0.05 by 1-way ANOVA compared with WT 
controls). Data are presented as mean ± SEM.
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Role of  RelB in mediating the cytoprotective effects of  TRAF2. To explore the contribution of  RelB to the 
cytoprotective phenotype observed in the Myh6-TRAF2LC mouse hearts, we crossed RelB
–/+ mice with 
Myh6-TRAF2LC mice and then performed I/R injury both ex vivo and in vivo. The baseline cardiac phe-
notype of  the RelB–/+ and Myh6-TRAF2LC/RelB
–/+ mice was not significantly different from WT mice 
at 12 weeks of  age (Supplemental Figure 4), with the exception that the percent fractional shortening 
(%FS) was significantly (P = 0.025) reduced, and the heart weight–to–body weight ratio (HW/BW) 
was significantly increased (P = 0.009) in the Myh6-TRAF2LC/RelB
–/+ mice compared with WT, con-
sistent with our prior observation that %FS is slightly decreased and the HW/BW slightly increased in 
Myh6-TRAF2LC mouse hearts (9). Despite these alterations in %FS and HW/BW, Myh6-TRAF2LC mice 
had a cytoprotective phenotype. To determine the functional effects of  RelB signaling, hearts from WT, 
Myh6-TRAF2LC, RelB
–/+, and Myh6-TRAF2LC/RelB
–/+ mice were subjected to 30 minutes of  no-flow 
ischemia, followed by 60 minutes of  reperfusion ex vivo. Figure 5A, shows that the degree of  functional 
recovery of  the RelB–/+ heterozygous mice was not significantly different (P = 0.962 overall) from WT 
mice. However, the salient finding shown by Figure 5A is that the improved recovery of  LV function 
observed in the Myh6-TRAF2LC mouse hearts relative to WT mouse hearts (P < 0.001 overall) was not 
evident in the Myh6-TRAF2LC/RelB
–/+ mouse hearts, which were not significantly different from WT 
mouse hearts (P = 0.064). To determine whether the loss of  functional recovery in the Myh6-TRAF2LC/
RelB–/+ mouse hearts was the result of  increased myocyte injury, we measured CK release and EBD 
uptake. As shown by the group data for CK in Figure 5B and the EBD uptake in Figure 5, C and D, the 
significant decrease in CK release (P = 0.044) and EBD (P = 0.029) uptake observed in the Myh6-TRA-
F2LC mouse hearts relative to WT mouse hearts was completely abrogated in the Myh6-TRAF2LC/
RelB–/+ mouse hearts. The degree of  CK release and EBD uptake was not significantly different from 
WT controls in the RelB–/+ mice (P = 0.334 for CK, P = 0.891 for EBD) or the Myh6-TRAF2LC/RelB
–/+ 
mouse hearts (P > 0.99 for CK, P > 0.99 for EBD).
Figure 5. Role of RelB in the mediating the protective effects of TRAF2 during I/R injury. (A) Percent recovery of LVDP following I/R injury of WT, 
Myh6-TRAF2LC, RelB
–/+, and Myh6-TRAF2LC/RelB
–/+ (n = 9–13/group) mouse hearts (*P < 0.05 compared with WT controls by repeated measures analysis 
using mixed models methodology). (B) Creatine kinase (CK) release measured in the effluent following 30 minutes of reperfusion (n = 6–9/group). (C) Rep-
resentative images Evans Blue dye (EBD) uptake (scale bar: 50 μm) (data are representative of 6 independent experiments). (D) Group data for EBD uptake 
(n = 5–9/group) (*P < 0.05 by 1-way ANOVA compared with WT controls). Data are presented as mean ± SEM.
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To further explore the role of  RelB in terms of  mediating the cytoprotective effects of  TRAF2, we 
performed closed-chest I/R studies in WT, Myh6-TRAF2LC, RelB
–/+, and Myh6-TRAF2LC/RelB
–/+ mice 
using 90 minutes of  ischemia, followed by 2 weeks of  reperfusion, as described (20). Figure 6A shows that 
there was no significant difference (P = 0.87 overall) in the area at risk in each of  the 4 groups of  mice at 
the time of  reperfusion. Figure 6B shows that the segmental wall motion score index (SWMSI), a noninva-
sive measurement of  infarct size (21), was significantly less (P = 0.028) for the Myh6-TRAF2LC mice when 
compared with WT mice 1 week after I/R injury in vivo. Although the SWMSI was numerically increased 
at 2 weeks in the Myh6-TRAF2LC mice, these values were not significantly different (P = 0.1) from the 
values at 1 week. However, the SWMSI at 1 week was not significantly different in the RelB–/+ (P = 0.824) 
and Myh6-TRAF2LC/RelB
–/+ (P > 0.99) mouse hearts when compared with WT mice. Two weeks after 
I/R injury, there was no significant difference in the LV end-diastolic volume, LV end-systolic volume, LV 
ejection fraction, or HW/BW ratio between the WT, Myh6-TRAF2LC, RelB
–/+, or Myh6-TRAF2LC/RelB
–/+ 
mouse hearts (Supplemental Figure 5).
Hearts were harvested and analyzed for fibrosis, using Masson’s trichrome staining (Figure 6, C and D) 
and Picrosirius red staining (Supplemental Figure 5), and the myocyte cross-sectional area was measured 
by staining with wheat germ agglutinin (WGA) (Figure 6, E and F). There was a significant decrease in 
trichrome staining (P = 0.0085; Figure 6, C and D) and Picrosirius red staining (P = 0.0406; Supplemental 
Figure 5) in the Myh6-TRAF2LC mouse hearts compared with WT mouse hearts; however, the degree of  
Figure 6. In vivo closed-chest I/R in WT, Myh6-TRAF2LC, RelB–/+, Myh6-TRAF2LC/RelB–/+ mice. (A) Area-at-risk (AAR) (n = 6–9 per group) (*P < 0.05 
by 1-way ANOVA compared with WT controls). (B) Segmental Wall Motion Score Index (SWMSI) (n = 6–10 per group) (*P < 0.05 compared with WT 
by repeated measures analysis using mixed models methodology). (C) Masson’s trichrome staining (scale bar: 1 mm) (representative images of 7 
independent experiments). (D) Quantification of group data for Masson’s trichrome staining (n = 10–12/group). (E) Representative images of wheat 
germ agglutinin (WGA) staining (scale bar: 50 μm) (data are representative of 3 independent experiments). (F) Group data of cardiac myocyte cell size 
based on WGA staining (n = 20 cells counted/section, 3 sections per heart, 3 mouse hearts per group) (*P < 0.05 by 1-way ANOVA compared with WT 
controls). Data are presented as mean ± SEM.
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Masson’s trichrome staining and Picrosirius red staining was not different in the RelB–/+ (P > 0.99 for tri-
chrome and Picrosirius red) or Myh6-TRAF2LC/RelB
–/+ (P > 0.99 for trichrome and Picrosirius red) mouse 
hearts when compared with WT mouse hearts. Figure 6E shows representative WGA staining of  myocyte 
cross-sectional area in the periinfarct zone in WT, Myh6-TRAF2LC, RelB
–/+, or Myh6-TRAF2LC/RelB
–/+ 
mouse hearts, whereas Figure 6F summarizes the results of  group data. As shown, myocyte cross-sectional 
area was significantly (P < 0.0001) less in the Myh6-TRAF2LC mouse hearts when compared with WT 
mouse hearts. Importantly, myocyte cross-sectional area was not significantly different in the RelB–/+ (P > 
0.99) or Myh6-TRAF2LC/RelB
–/+ (P = 0.12) mouse hearts relative to WT mouse hearts, suggesting that the 
protective effects of  TRAF2 were abrogated in mouse hearts that were haploinsufficient for RelB.
Transcriptional targets of  TRAF2-mediated NF-κB signaling. Several downstream NF-κB targets of  TRAF2 
were identified by microarray analysis (Supplemental Table 1). One of  the genes that was differentially 
regulated in the Myh6-TRAF2LC and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts was TNFAIP3-inter-
acting protein 1 (Tnip1). Tnip1 codes for ABIN-1, which is a family member of  the A20 binding inhib-
itors of  NF-κB and apoptosis signaling (ABIN). ABINs bind to the ubiquitin-editing NF-κB inhibitor 
protein A20 (TNF-induced protein 3; TNFAIP3) and thus serve as negative feedback inhibitors of  canon-
ical NF-κB–mediated signaling (22). Given that canonical NF-kB–mediated signaling was suppressed in 
the Myh6-TRAF2LC mouse hearts, we asked whether noncanonical NF-kB signaling contributed to the 
observed increased in Tnip1 expression in Myh6-TRAF2LC mouse hearts. We first confirmed the results of  
Figure 7. TRAF2-mediated upregulation of ABIN-1. (A) qPCR quantification of Tnip1 (gene name for ABIN1 protein) in WT, Myh6-TRAF2LC, and Myh6-TRA-
F2LC/Myh6-IκBαΔN mouse hearts (n = 4/group). (B) qPCR quantification of Tnip1 in WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/RelB–/+ mouse hearts (n = 3–4/
group). (C) Western blot analysis of ABIN1 in WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts (n = 3/group). (D) Western blot analysis 
of ABIN1 in WT, Myh6-TRAF2LC, and Myh6-TRAF2LC/RelB
–/+ mouse hearts (n = 3/group). (E) ChIP assay of Tnip1 promoter using antibodies to members of 
the NF-κB family (n = 3/group) (*P < 0.05 by 1-way ANOVA compared with WT controls). Data are presented as mean ± SEM.
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the microarray analysis by quantitative PCR (qPCR) and Western blot analysis in the WT, Myh6-TRAF2LC, 
Myh6-TRAF2LC/Myh6-IκBαΔN, and Myh6-TRAF2LC/RelB
–/+ mouse hearts. As shown in Figure 7, mRNA 
levels of  Tnip1 were significantly increased (P = 0.045) in Myh6-TRAF2LC mouse hearts when compared 
with WT mouse hearts, whereas the level of  expression of  Tnip1 mRNA in Myh6-TRAF2LC/Myh6-IkBαΔN 
mice (Figure 7A) and Myh6-TRAF2LC/RelB
–/+ (Figure 7B) mouse hearts was not significantly different 
from WT mice (P > 0.99 for both). Importantly, Western blot analysis demonstrated that protein levels 
of  ABIN-1 were significantly upregulated (P = 0.022) in the Myh6-TRAF2LC mouse hearts relative to WT 
(Figures 7, C and D), whereas ABIN-1 protein levels were not significantly elevated in the Myh6-TRAF2LC/ 
Myh6-IκBαΔN mice (Figure 7C) and Myh6-TRAF2LC/RelB
–/+ (Figure 7D) mouse hearts (P = 0.9716 and 
P > 0.999, respectively). To determine whether noncanonical NF-κB signaling was responsible for the 
observed increased in expression of  Tnip1 in Myh6-TRAF2LC mouse hearts, we performed a ChIP assay. As 
shown in Figure 7E, there was an increase in RelB binding to the Tnip1 promoter in Myh6-TRAF2LC mouse 
hearts, whereas RelB binding was not detected in the WT mouse hearts. In contrast, the levels of  p50, p52, 
and p65 binding to the Tnip1 promoter were relatively unchanged in the Myh6-TRAF2LC and WT mouse 
hearts. Although Nfkbie was not identified in our microarray analysis using an FDR < 0.05, when we used 
a more relaxed FDR (<0.20), we observed that the expression of  Nfkbie was also differentially regulated in 
the Myh6-TRAF2LC and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. Supplemental Figure 6 shows that 
the expression of  IκBε (mRNA and protein) was significantly increased in Myh6-TRAF2LC mouse hearts 
when compared with WT mouse hearts, whereas the expression level of  IκBε (mRNA and protein) was 
Figure 8. Proposed model for TRAF2-mediated crosstalk between canonical noncanonical NF-κB–mediated signaling pathways. TRADD, TNF receptor 
type 1–associated DEATH domain protein; RIP, receptor-interacting protein kinase; TRAF2, TNF receptor–associated factor 2; TNIP1, TNFAIP3-interacting 
protein 1; NEMO, NF-κB essential modulator; IKKα, inhibitor of NF-κB kinase subunit α; IKKβ, inhibitor of NF-κB kinase subunit β; IκBα, NF-κB inhibitor α, 
NIK, NF-κβ–inducing kinase (also known as MAPK kinase kinase 14; MAP3K14); NFKBIE, NF-κB inhibitor epsilon; IκBε, NF-κB inhibitor ε.
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normalized in the Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. In addition, we detected increased RelB 
binding to the Nfkbie promoter in Myh6-TRAF2LC mouse hearts, whereas RelB binding was not detected in 
the WT mouse hearts. Viewed together, these results implicate an important role for RelB with respect to 
TRAF2-mediated Tnip1 and Nfkbie gene expression.
Discussion
Although it has long been recognized that activation of  the innate immune system confers cytoprotective 
responses in the heart, the precise mechanisms that are responsible for these beneficial effects are not well 
known. Here, we show that TRAF-mediated cytoprotective responses in the heart require crosstalk between 
the canonical and noncanonical NF-κB signaling pathways. Three compelling lines of  information support 
this statement. First, LV functional recovery was significantly improved and the extent of  LV tissue injury 
was significantly less following I/R injury in Myh6-TRAF2LC when compared with control mice (Figure 1), 
consistent with our prior observations (9). Remarkably, the cytoprotective effects of  TRAF2 were complete-
ly abolished in double-transgenic Myh6-TRAF2LC/Myh6-IκBαΔN mice that lack NF-κB signaling through 
the canonical pathway (23). To determine whether activation of  the SAFE pathway was required for the 
cytoprotective effects of  TRAF2, as has been reported for TNF-mediated preconditioning and/or postcon-
ditioning (15, 16), we performed I/R injury ex vivo in the presence or the absence of  AG490, a STAT3 
inhibitor. Although STAT3 was significantly activated in the Myh6-TRAF2LC mouse hearts relative to WT 
control mice (Supplemental Figure 2), and STAT3 activation was abrogated by treatment with AG490, 
inhibition of  STAT3 did not attenuate the improved recovery of  LV function, nor did it attenuate the 
decrease in LV tissue injury in the Myh6-TRAF2LC mouse hearts (Figure 2), suggesting that while STAT3 is 
activated in Myh6-TRAF2LC mouse hearts, it is not required for the cytoprotective effects of  TRAF2.
Second, to elucidate the potential mechanism(s) for the NF-κB–mediated cytoprotective effects of  
TRAF2, we performed Western blotting for NF-κB family members, p65 (RelA), p50, p52, and RelB, as 
well as DNA binding assays on nuclear extracts from WT, Myh6-TRAF2LC, Myh6-IκBαΔN, or Myh6-TRA-
F2LC/Myh6-IκBαΔN mouse hearts. We observed increased expression levels and increased DNA binding 
of  NF-κB family members that are traditionally associated with noncanonical NF-κB signaling, namely 
p52 and RelB (Figure 4), whereas there was no increase in expression or DNA binding of  the p50 and 
p65 subunits, which are traditionally associated with canonical NF-κB signaling. Importantly, the increase 
in expression and DNA binding of  the p52 and RelB subunits in the Myh6-TRAF2LC mouse hearts were 
normalized in Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts that lacked canonical NF-κB signaling (Fig-
ure 4), suggesting that there was crosstalk between the canonical and noncanonical NF-κB pathways (19). 
Third, to determine whether activation of  noncanonical NF-κB signaling was responsible for the observed 
cytoprotective effects of  TRAF2, we performed I/R injury ex vivo and in vivo in Myh6-TRAF2LC mice that 
were haploinsufficient for RelB (Myh6-TRAF2LC/RelB
–/+ mice). Figures 5 and 6 show that the improved 
LV functional recovery in Myh6-TRAF2LC mouse hearts was attenuated in the Myh6-TRAF2LC/RelB
–/+ 
mice ex vivo (Figure 5A) and in vivo (Figure 6B). Moreover, the TRAF2-mediated decrease in tissue injury 
(Figures 5, B–D) and myocardial fibrosis (Figure 6, C and D, and Supplemental Figure 5) observed in the 
Myh6-TRAF2LC mouse hearts was abrogated in the Myh6-TRAF2LC/RelB
–/+ mouse hearts. These results, 
when viewed together, suggest that crosstalk between the canonical and noncanonical NF-κB signaling 
pathways is required for mediating the cytoprotective effects of  TRAF2.
Crosstalk between canonical and noncanonical NF-κB signaling. Activation of  NF-κB results in the induc-
tion of  a panoply of  biological responses ranging from cellular stress responses, cell survival, immune 
responses, and cell maturation. Based on the components of  the signaling cascade, NF-κB signaling is 
broadly categorized into canonical and noncanonical pathways, which are mediated through different cell 
surface receptors, cytoplasmic adaptors, and NF-κB homo- and heterodimers. Activation of  the canonical 
NF-κB pathway provides rapid responses (within minutes), both in terms of  activation and deactivation, 
and occurs in response to a broad variety of  environmental stimuli. In contrast, the noncanonical pathway 
is comparatively slower (activated within hours) and is more persistent. Although these 2 pathways have 
been regarded as functionally distinct parallel signaling pathways, more recent studies have shown that 
there is bidirectional crosstalk between canonical and noncanonical signaling (19).
Here, we show that crosstalk between the canonical and noncanonical NF-κB pathways is responsible 
for mediating the cytoprotective effects of  TRAF2 ex vivo and in vivo, and that this crosstalk occurs at 
several different interdependent levels, including increased synthesis of  RelB, increased processing of  p100, 
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and increased synthesis of  proteins that directly inhibit canonical NF-κB signaling (ABIN-1 and IκBε). Our 
data suggest that canonical NF-κB–induced expression of  RelB contributed to activation of  noncanoni-
cal signaling in the Myh6-TRAF2LC mouse hearts, given that the significant increase in RelB expression 
in the Myh6-TRAF2LC mouse hearts was abrogated in the Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts 
that lacked canonical NF-κB signaling. Although canonical NF-κB–induced expression of  RelB has been 
reported to promote or inhibit signaling through the noncanonical pathway (19), our results suggest that 
RelB-mediated activation of  noncanonical signaling is required for the cytoprotective effects of  TRAF2, 
insofar as the cytoprotective effects of  TRAF2 were absent in mice that were haploinsufficient for RelB 
signaling. Further, a ChIP assay revealed the presence of  RelB on the promoter regions of  Tnip1 and Nfkbie, 
which were upregulated in the Myh6-TRAF2LC mouse hearts but not in Myh6-TRAF2LC/Myh6-IκBαΔN 
mouse hearts, suggesting that NF-κB induction promoted increased RelB-mediated signaling. While we 
were unable to demonstrate that increased stabilization of  NIK was responsible for activation of  nonca-
nonical signaling, we did observe increased processing of  p100 to p52 in Myh6-TRAF2LC mouse hearts 
(Supplemental Figure 3), consistent with increased NIK signaling. Given that NIK is degraded rapidly, 
and therefore difficult to detect in vivo, we cannot exclude the formal possibility that NIK stabilization was 
responsible for the observed increase in p100 processing. The results of  this study suggest (but do not prove) 
that there is a third level of  interaction between the canonical and noncanonical signaling pathways in the 
Myh6-TRAF2LC mouse hearts that is mediated by RelB-mediated upregulation of  inhibitory proteins that 
dampen signaling through canonical NF-κB signaling, including ABIN-1 (Tnip1). ABIN-1 inhibits canon-
ical NF-κB signaling by physically linking A20 with NEMO, thus facilitating A20-mediated deubiquitina-
tion of  NEMO-mediated canonical NF-κB signaling (22), increased expression of  IκBε — which directly 
inhibits nuclear translocation of  p50 and p65 — and increased nuclear translocation of  p100 (IκBδ) — 
which is able to sequester RelA:p50 homodimers, thereby by dampening canonical NF-κB signaling (24). 
Additional studies will be required to determine the functional significance of  RelB-mediated dampening 
of  canonical NF-κB signaling.
Conclusions. Whereas the role of  canonical NF-κB signaling in the heart in response to cardiac injury 
has been characterized extensively (25), this is the first study to our knowledge to delineate the impor-
tance of  noncanonical NF-κB signaling in the heart. Here, we suggest that TRAF2 serves as a scaffolding 
protein that integrates canonical and noncanonical NF-κB signaling in the heart, thereby providing the 
cardiac myocyte with a broad repertoire of  cellular responses to tissue injury, including a brisk inflamma-
tory response mediated by the canonical NF-κB signaling and a slower secondary noncanonical response 
that is more sustained, and confers cytoprotection by upregulating RelB-dependent cytoprotective genes, 
as well as by dampening canonical NF-κB signaling, which — if  dysregulated — can lead to excessive col-
lateral tissue damage (Figure 8). The observation that sustained TRAF2 signaling conveys cytoprotective 
responses is consistent with recent clinical observations that have identified TRAF2 as a tumor oncogene 
and studies that have linked sustained noncanonical NF-κB signaling with cancer initiation and tumor 
maintenance (26, 27). Although the full ensemble of  noncanonical NF-κB–induced cytoprotective genes 
is not known, we have shown previously that the cytoprotective effects of  TRAF2 are mediated, at least in 
part, by RelB-mediated expression of  dysferlin (Dysf), which is an “emergency response” gene that facili-
tates membrane repair (13). Viewed together, these results offer a significant revision of  NF-κB signaling in 
the heart, providing important insights that allow for a reconciliation of  the divergent reports of  the dele-
terious and beneficial effects of  NF-κB signaling in the heart, and they suggest that a better understanding 
of  how canonical and noncanonical signals are integrated in the heart following tissue injury represents an 
opportunity for developing novel therapeutic interventions that maximize the beneficial effects of  NF-κB 
signaling without incurring the untoward deleterious effects of  dysregulated NF-κB signaling.
Methods
Transgenic mouse lines
The lines of  transgenic mice overexpressing TRAF2 and a mutated IκBα (IκBαΔN) transgene under the 
control of  the Myh6 promoter (Myh6-TRAF2LC and Myh6-IκBαΔN, respectively) have been described pre-
viously (9, 23). To determine whether the cardioprotective effects of  TRAF2 were mediated through an 
NF-κB–dependent pathway, we crossed Myh6-TRAF2LC mice (FVBN) with Myh6-IκBαΔN mice (C57BL/6) 
to generate Myh6-TRAF2LC/Myh6-IκBαΔN double-transgenic mice. The F1 generation of  this cross was 
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employed in all experiments described herein. RelB-deficient mice were obtained from The Jackson Lab-
oratory (C57BL/6-RelbTg(H2-K1/GH1)106Bri/J) (28) and were outcrossed onto the FVBN background 6 times. 
In contrast to the homozygous C57BL/6 RelB–/– mice, which develop a wasting syndrome by 3 weeks 
and die between 3 weeks to several months (28), we observed that the RelB–/– mice bred onto the FVBN 
background died at approximately 5–6 weeks of  age. Therefore, we used FVBN RelB–/+ heterozygous mice 
for all experiments. To determine whether the cardioprotective effects of  TRAF2 were mediated through 
a RelB-dependent pathway, we crossed Myh6-TRAF2LC mice (in an FVB/N background) with RelB
–/+ (in 
an FVB/N background) mice to generate a line of  Myh6-TRAF2LC/RelB
–/+ mice. The Myh6-TRAF2LC/
RelB–/+ mice were born with the expected Mendelian frequency and had normal life spans. All mice were 
maintained in a pathogen-free environment and were fed pellet food and water ad libitum.
I/R injury ex vivo
Hearts from 10- to 12-week-old male Myh6-TRAF2LC, Myh6-IκBαΔN, Myh6-TRAF2LC/Myh6-IκBαΔN, 
RelB–/+, and Myh6-TRAF2LC/RelB
–/+ mice, and their respective littermate (LM) and/or WT controls, were 
isolated and perfused at a constant pressure of  70 mm Hg with modified Krebs-Henseleit buffer (Milli-
poreSigma) as described previously (13). After a 20-minute stabilization period, mouse hearts were subject-
ed to no-flow ischemia (time [t] = 0 minutes) for 30 minutes followed by reperfusion (t = 30 minutes) for 
up to 60 minutes (t = 90 minutes). To determine whether activation of  the STAT3 signaling pathway was 
responsible for mediating the cytoprotective effects of  TRAF2, we treated WT and Myh6-TRAF2LC mouse 
hearts in separate experiments with 10 μM AG490 (MilliporeSigma), a tyrphostin tyrosine kinase inhibitor 
that blocks signaling through the JAK/STAT pathway, which was added to Krebs-Henseleit buffer (Milli-
poreSigma) or an equivalent volume of  diluent (0.06% ethanol). Mouse hearts were treated for 15 minutes 
following the 20-minute stabilization period and during the first 15 minutes of  the reperfusion period.
Assessment of cardiac myocyte injury after I/R injury
To assess the degree of  myocyte injury after I/R injury ex vivo, we assessed CK release in the effluent 30 
minutes after reperfusion in 10- to 12-week-old male WT, Myh6-TRAF2LC, Myh6-IκBαΔN, Myh6-TRA-
F2LC/Myh6-IκBαΔN, RelB
–/+, and Myh6-TRAF2LC/RelB
–/+ mouse hearts, as previously described (9). CK 
activity was normalized for dry heart weight, and data were expressed as units per gram of  cardiac tissue. 
Because triphenyltetrazolium chloride staining may underestimate the true extent of  tissue injury within 
the first 3 hours of  cardiac injury (29), we used EBD (MilliporeSigma) uptake to assess the degree of  myo-
cardial tissue injury after I/R injury, as described (9, 13). Mouse hearts were examined at the level of  the 
papillary muscle using a total of  15 microscopic fields per heart. Data are expressed as the percent area of  
the myocardium with red fluorescence.
I/R injury in vivo
Hearts from WT, Myh6-TRAF2LC, RelB
–/+, and Myh6-TRAF2LC/RelB
–/+ were subjected to I/R injury, using the 
closed-chest I/R model developed by Entman and colleagues (30), and modified as we have described previous-
ly (31). For the studies described herein, we used 10- to 12-week-old male mice that were anesthetized with 1.5% 
isoflurane and were then subjected to 90 minutes of closed-chest ischemia, followed by reperfusion for 2 weeks. 
Sham-operated animals underwent the identical procedure, with the exception that ischemia was not induced.
Echocardiographic studies
Image acquisition. Ultrasound examination of the cardiovascular system was performed using a Vevo 2100 Ultra-
sound System (VisualSonics Inc.) equipped with a 30 MHz linear-array transducer, as previously described (31).
Imaging protocol. Mice were imaged by echocardiography at 1 day, 1 week, and 2 weeks after I/R injury 
to evaluate LV structure and function, as described (32).
Quantification of  area at risk and infarct size. Noninvasive evaluation of  area at risk and infarct size was 
performed as described using the SWMSI (33). The SWMSI represents the sum of  the abnormal segments 
of  the LV wall motion obtained from serial short-axis views divided by the total number of  segments of  the 
LV wall (values very from 0–1). Prior studies have shown that SWMSI correlates with acute and chronic 
infarct size as well as area at risk (21,32). Isoflurane (1.5% inhaled via nose cone) was used during ischemia 
and avertin (0.005 ml/g) was used for sedation for imaging at 1 and 2 weeks based on previously estab-
lished methods for infarct quantitation in vivo (31).
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Histologic analysis
Two weeks after I/R injury in vivo, the mice were euthanized, and the mouse hearts were removed and 
weighed to determine the HW/BW ratio. Mouse hearts were processed, paraffin-embedded, and stained with 
H&E, Masson’s trichrome, and Picrosirius red staining, as described (20). To estimate the volume fraction (%) 
of  collagen, serial sections of  Masson’s trichrome– or Picrosirius red–stained sections were quantified using 
color thresholding by ImageJ software (NIH), and data were expressed as the average percentage of  the LV 
stained. Two midpapillary sections per heart (n = 5–6 per group) were quantified. To evaluate myocyte size, 
sections were deparaffinized, rehydrated, and stained with fluorescent rhodamine–conjugated wheat germ 
agglutinin at 5μg/ml in 1% BSA, 1× TBS (Vector Laboratories). Fluorescence was visualized using a Zeiss 
confocal microscope, and digital images were analyzed and measured with Zeiss Axiovision software (34).
RNA extraction and microarray analysis
Hearts from 10- to 12-week-old male WT, Myh6-TRAF2LC, Myh6-IκBαΔN, and Myh6-TRAF2LC/ 
Myh6-IκBαΔN (n = 4 per group) mice were used for transcriptional profiling. Total RNA was extracted 
from mouse hearts using the RNEasy Fibrous Tissue Midi kit (Qiagen), according to the manufacturer’s 
instructions. Gene expression analysis was performed using the Sentrix BeadChip and BeadStation system 
from Illumina Inc. RNA was further processed and hybridized to a Mouse Ref-6 BeadChip array (Illumina 
Inc.). The mouse Ref-6 BeadChips contain sequences representing approximately 46,000 curated genes 
and ESTs. After scanning the probe array, the resulting image was analyzed using the BeadStudio software 
(Illumina Inc.). Samples were normalized using a cubic spline procedure, and the average signal for each 
probeset was determined. All such average probe set signals were used to determine intra- and intergroup 
variance using a principal components analysis plot in Partek Genome Studio 6.6 (Partek). Differentially 
expressed genes were assessed using 1-way ANOVA model with contrasts in Partek Genome Studio 6.6, 
with a cutoff  of  an absolute fold-change above 1.2 and FDR < 0.05, unless otherwise noted. Selected differ-
entially expressed gene profiles across all 16 mouse hearts were displayed using unsupervised hierarchical 
clustering with Euclidean distance and average linkage (Partek Genome Studio 6.6). Microarray data has 
been deposited to the NCBI Gene Expression Omnibus (GEO GSE107668).
Activation of NF-κB and STAT3
We used 2 different approaches to assess NF-κB activation in the hearts of  the WT, Myh6-TRAF2LC, Myh6-
IκBαΔN, and Myh6-TRAF2LC/Myh6-IκBαΔN mice. Whole heart tissue from 10- to 12-week-old male mice 
was homogenized and separated into cytoplasmic and nuclear fractions using the NE-PER Nuclear and Cyto-
plasmic Extraction reagents (ThermoFisher Scientific). We first performed Western blotting for RelB (catalog 
4954, Cell Signaling Technology), p50 (catalog 32360, Abcam), p52 (catalog 4882, Cell Signaling Technolo-
gy), and p65 (catalog 8242, Cell Signaling Technology) in nuclear and cytosolic extracts. For loading controls, 
the samples for nuclear extracts were normalized by RNA pol II (catalog 05-623, MilliporeSigma), whereas 
GAPDH (catalog 22555, Abcam) was used as a loading control for cytosolic extracts. Western blotting was 
also performed for NIK on total cell lysates (catalog 4994, Cell Signaling Technology). Protein expression was 
visualized using horseradish peroxidase–conjugated donkey anti-rabbit or donkey anti-mouse secondary anti-
body (1:5,000; Cell Signaling Technology) and Pierce Supersignal West Dura Extended Duration Substrate 
(ThermoFisher Scientific) and detected using the Kodak Imagine Station 4000R Pro.
We also examined NF-κB activation in nuclear extracts from 10- to 12-week-old male WT, Myh6-TRA-
F2LC, Myh6-IκBαΔN, and Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts, using the TransAM NF-kB family 
transcription factor assay (Active Motif), according to manufacturer’s instructions (17). Ninety-six–well plates 
coated with a DNA probe containing the NF-κB consensus binding site were incubated with 20 μg of  nuclear 
extract, followed by incubation with antibodies to p65, p50, p52, or RelB included in the kit. HRP-conjugated 
secondary antibody incubation was then performed and the plate was developed. Absorbance was measured 
with the Bio-Rad 680 Microplate Reader. Data represent the average of  duplicate samples from each heart.
To determine STAT3 activation in WT and Myh6-TRAF2LC mouse hearts, Western blotting was per-
formed on nuclear and cytosolic myocardial extracts from 12-week-old mouse hearts that were subjected 
to the same ex vivo I/R protocol described above with the diluent or 10 μM AG490. Mouse hearts were 
collected after the first 15 minutes of  reperfusion for lysate preparation. We measured phospho-STAT3 
using an antibody (catalog 9145, Cell Signaling Technology) that measures Tyr705 phosphorylation, which 
is responsible for STAT3 activation, dimerization, nuclear translocation, and DNA binding (35). The blots 
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were stripped using the Restore Plus Western Blot Stripping Buffer (ThermoFisher Scientific) and reprobed 
with an antibody to total STAT3 (catalog 9139, Cell Signaling Technology), and the final results were 
expressed as the ratio of  phosphorylated STAT3/total STAT3.
ChIP assay and qPCR
ChIP assay was performed on Tnip1 and Nfkbie, which were chosen as candidate genes whose expression 
was mediated by NF-κB–mediated signaling. ChIP assay was performed using the EZ-ChIP Assay Kit 
(MilliporeSigma) following the manufacturer’s instructions, exactly as described previously (13). Chroma-
tin was immunoprecipitated with antibodies against NF-κB family members (RelB, sc-226, Santa Cruz Bio-
technology Inc.; p50, ab7971, Abcam; p65, catalog 8242, Cell Signaling Technology; p52, ab7972, Abcam) 
or control antibodies overnight at 4°C with rotation. PCR was performed with 4 μl of  immunoprecipitated 
DNA using the following primers for the Tnip1 promoter: forward 5′ GACTCAGCAAGACTCAGCATC 
3′, reverse 5′ TCAAGCAAAGGCAGGTACAA 3′. Tnip1 primers were based on a consensus κB site pre-
dicted in the mouse promoter by PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.
cgi?dirDB=TF_8.3) 383 bp upstream of  the transcription start site. Gurevich et al. also described consensus 
κB sites in similar locations in the human Tnip1 promoter (36).
The following primers were used for the Nfkbie promoter: forward 5′CACGCAGGAGTGAGT-
CAAGA 3′, reverse 5′ AAAGGAGCTTCCGGGTAGAG 3′ (37). Tnip1 and Nfkbie mRNA expression 
were confirmed by qPCR and Western blotting in 12-week-old WT, Myh6-TRAF2LC, Myh6-IκBαΔN, and 
Myh6-TRAF2LC/Myh6-IκBαΔN mouse hearts. qPCR was performed on an ABI 7500 Fast Real-Time PCR 
System (Applied Biosystems). RNA (2 μg of  total) was reverse-transcribed into cDNA using SuperScript 
III First strand synthesis system (ThermoFisher Scientific). cDNAs were then evaluated for 18S rRNA (cat-
alog 4333760F), Tnip1 (Mm01288484_m1), and Nfkbie (Mm01269649_m1) content using TaqMan gene 
expression assay (Applied Biosystems). Western blotting was performed using a monoclonal antibody for 
ABIN-1 (Tnip1) (catalog 37-6100, Invitrogen) and a polyclonal antibody for IκBε (catalog AF4637, R&D 
systems); GAPDH (catalog 22555, Abcam) was used as the loading control.
Statistics
Data are expressed as means ± SEM. One-way ANOVA with Bonferroni post-hoc analysis (Graphpad 
Prism) was used to test for differences in HW/BW ratios, CK release, EBD uptake, densitometry, Tri-
chrome and Picrosirius red staining, cell area, and qPCR, whereas t tests (2-tailed) were used when com-
paring only 2 groups. For repeated measures analysis, (2-D echocardiograhic and Langendorff  perfusion 
data), mixed models methodology was used. Group, time, and the interaction between group and time 
were all entered into the model. Time was treated as a categorical variable. The interaction was evaluated 
to determine if  the relationship between group and LVDP varied with respect to time. Based on the Akaike 
Information Criteria (AIC) and Shwarz Information Critieria (BIC), an unstructured variance-covariance 
matrix was used to model the repeated measurements. Group means were based on model results, and 
differences between groups were determined overall and within each time point. All pair-wise comparisons 
were considered. Test results were adjusted based on Sidak’s method to control the overall type I error rate. 
A value of  P < 0.05 was considered statistically significant.
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